N-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)-4-(thiazol-4-yl)benzamide

Catalog No. :
ACZNYD371
CAS No. :
1580000-17-4
Molecular Formula :
C25H30N4O2S
Molecular Weight :
450.61

IUPAC Name:N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-(thiazol-4-yl)benzamide

N-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)-4-(thiazol-4-yl)benzamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)-4-(thiazol-4-yl)benzamide
IUPAC NameN-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-(thiazol-4-yl)benzamide
Molecular FormulaC25H30N4O2S
Molecular Weight450.61
SMILESO=C(NCCCCN1CCN(C2=CC=CC=C2OC)CC1)C3=CC=C(C4=CSC=N4)C=C3
InChI KeyRGWFVVKSJUSKTE-UHFFFAOYSA-N
SynonymN-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)-4-(thiazol-4-yl)benzamide;OS-3-106;Benzamide, N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-4-(4-thiazolyl)-;N-{4-[4-(2-Methoxyphenyl)-1-piperazinyl]butyl}-4-(1,3-thiazol-4-yl)benzamide;OS-3-106 >=98% (HPLC);Inhibitor,inhibit,Dopamine Receptor,HEK 293 cells,self-administration,arylamide phenylpiperazine,OS 3 106,psychostimulant addiction,cocaine,sucrose,OS3106;OS-3-106, 10 mM in DMSO
CAS No.1580000-17-4

Synthetic Route by SureRoute

1. ACZNYD371 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACZNYD371 route product structure diagram
    ACZNYD3711580000-17-4
Inquiry

2. ACZNYD371 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACZNYD371 route product structure diagram
    ACZNYD3711580000-17-4
Inquiry

Comments (0)